Bourne Lent Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $485K | Hold |
3,480
| – | – | 0.18% | 43 |
|
|
2025
Q4 | $427K | Hold |
3,480
| – | – | 0.14% | 45 |
|
|
2025
Q3 | $386K | Hold |
3,480
| – | – | 0.14% | 47 |
|
|
2025
Q2 | $386K | Hold |
3,480
| – | – | 0.15% | 46 |
|
|
2025
Q1 | $390K | Sell |
3,480
-100
| -3% | -$10.3K | 0.17% | 43 |
|
|
2024
Q4 | $331K | Hold |
3,580
| – | – | 0.13% | 47 |
|
|
2024
Q3 | $300K | Hold |
3,580
| – | – | 0.11% | 51 |
|
|
2024
Q2 | $246K | Hold |
3,580
| – | – | 0.09% | 58 |
|
|
2024
Q1 | $262K | Hold |
3,580
| – | – | 0.11% | 53 |
|
|
2023
Q4 | $290K | Sell |
3,580
-5,000
| -58% | -$389K | 0.12% | 51 |
|
|
2023
Q3 | $643K | Hold |
8,580
| – | – | 0.28% | 36 |
|
|
2023
Q2 | $661K | Hold |
8,580
| – | – | 0.23% | 37 |
|
|
2023
Q1 | $712K | Hold |
8,580
| – | – | 0.27% | 35 |
|
|
2022
Q4 | $737K | Buy |
8,580
+100
| +1% | +$7.92K | 0.32% | 34 |
|
|
2022
Q3 | $523K | Buy |
8,480
+100
| +1% | +$6.31K | 0.23% | 36 |
|
|
2022
Q2 | $518K | Hold |
8,380
| – | – | 0.21% | 39 |
|
|
2022
Q1 | $498K | Buy |
8,380
+200
| +2% | +$12.8K | 0.16% | 43 |
|
|
2021
Q4 | $594K | Hold |
8,180
| – | – | 0.16% | 40 |
|
|
2021
Q3 | $571K | Hold |
8,180
| – | – | 0.16% | 41 |
|
|
2021
Q2 | $563K | Buy |
8,180
+525
| +7% | +$35.1K | 0.16% | 41 |
|
|
2021
Q1 | $495K | Buy |
7,655
+200
| +3% | +$12.9K | 0.16% | 42 |
|
|
2020
Q4 | $434K | Hold |
7,455
| – | – | 0.14% | 44 |
|
|
2020
Q3 | $471K | Hold |
7,455
| – | – | 0.18% | 39 |
|
|
2020
Q2 | $574K | Hold |
7,455
| – | – | 0.25% | 35 |
|
|
2020
Q1 | $557K | Buy |
7,455
+2,000
| +37% | +$138K | 0.3% | 34 |
|
|
2019
Q4 | $354K | Buy |
+5,455
| New | +$355K | 0.17% | 42 |
|
|
2017
Q2 | – | Sell |
-3,130
| Closed | -$213K | – | 60 |
|
|
2017
Q1 | $213K | Hold |
3,130
| – | – | 0.12% | 57 |
|
|
2016
Q4 | $224K | Buy |
3,130
+250
| +9% | +$18.6K | 0.13% | 57 |
|
|
2016
Q3 | $228K | Buy |
+2,880
| New | +$234K | 0.17% | 49 |
|
|
2016
Q1 | – | Sell |
-2,000
| Closed | -$202K | – | 50 |
|
|
2015
Q4 | $202K | Buy |
+2,000
| New | +$208K | 0.15% | 50 |
|
|
2015
Q3 | – | Sell |
-2,000
| Closed | -$234K | – | 50 |
|
|
2015
Q2 | $234K | Buy |
+2,000
| New | +$219K | 0.18% | 49 |
|
Other funds holding GILD
VCM
VPM
Bourne Lent Asset Management's GILD Position: Q1 2026 in Review
Bourne Lent Asset Management held its Gilead Sciences (GILD) position steady in Q1 2026 at 3,480 shares worth $485K. The position accounts for 0.18% of the portfolio, ranked #43.
Bourne Lent Asset Management first reported a position in GILD in Q2 2015 and has held it in 31 quarters since. The position peaked at $737K in Q4 2022. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Bourne Lent Asset Management held 3,480 shares of Gilead Sciences worth $485K as of Q1 2026.
- Bourne Lent Asset Management left its Gilead Sciences share count unchanged in Q1 2026.
- Gilead Sciences made up 0.18% of Bourne Lent Asset Management's portfolio in Q1 2026, its #43 holding.
- Bourne Lent Asset Management first reported a position in Gilead Sciences in Q2 2015 and has held it in 31 quarters since.
- Bourne Lent Asset Management's Gilead Sciences position peaked at $737K in Q4 2022.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Bourne Lent Asset Management's 13F filing for Q1 2026, filed 17 Apr 2026.